Wordt geladen...
Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
BACKGROUND: Anti-interleukin (IL)-5 monoclonal antibodies as an eosinophil-depleting strategy is well established, with Mepolizumab being the first biologic approved as an adjunct treatment for severe eosinophilic asthma. CASE PRESENTATION: A 62-year old woman diagnosed with severe eosinophilic asth...
Bewaard in:
| Gepubliceerd in: | Allergy Asthma Clin Immunol |
|---|---|
| Hoofdauteurs: | , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5216532/ https://ncbi.nlm.nih.gov/pubmed/28070196 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13223-016-0174-5 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|